Rebecca Buzzeo - Mar 31, 2023 Form 3 Insider Report for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)

Role
Chief Commercial Officer Exhibit 24.1 - Power of Attorney
Signature
/s/ Kurt Oreshack, by power of attorney for Rebecca Buzzeo
Stock symbol
MRVI
Transactions as of
Mar 31, 2023
Transactions value $
$0
Form type
3
Date filed
4/6/2023, 06:34 PM
Next filing
Nov 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRVI Class A Common Stock 85.8K Mar 31, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MRVI Employee Stock Options (Right to Buy) Mar 31, 2023 Class A Common Stock 85K $15.52 Direct F3
holding MRVI Employee Stock Options (Right to Buy) Mar 31, 2023 Class A Common Stock 75.4K $14.99 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 43,132 of such securities represent restricted stock units (the "2022 RSUs")") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Plan"). Each 2022 RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The 2022 RSUs will vest in 1/3rd increments on each of November 15, 2023, November 15, 2024, and November 15, 2025, subject to the Reporting Person's continued employment with the Issuer.
F2 42,651 of such securities represent restricted stock units (the "2023 RSUs") awarded under the Plan. Each 2023 RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The 2023 RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer.
F3 Represents options awarded under the Plan. These options will vest 1/48th on April 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer.
F4 Represents options awarded under the Plan. These options will vest 25% on November 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

Chief Commercial Officer Exhibit 24.1 - Power of Attorney